GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Net Intangibles Purchase And Sale

Medicenna Therapeutics (TSX:MDNA) Net Intangibles Purchase And Sale : C$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Medicenna Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was C$0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil.

Medicenna Therapeutics Net Intangibles Purchase And Sale Historical Data

The historical data trend for Medicenna Therapeutics's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Net Intangibles Purchase And Sale Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medicenna Therapeutics Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
TSX:RVX TSXV:SBM XCNQ:DOSE TSXV:NRX NEOE:BMND TSXV:IBT XCNQ:MDMA XCNQ:COOL XCNQ:TELI TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MDNAF:USA
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Website
https://www.medicenna.com
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines